drugset / Trial / NCT02034630

Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRD

NCT02034630

Phase 1/2 Unknown 5 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the outcome of hematopoietic stem cell transplantation using targeted busulfan, fludarabine conditioning regimen in genetic rare disease

Timeline

Start
2014-07-21
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 80 mg/m2 Intravenous
Subject Busulfan Small molecule 120 mg/m2 Intravenous